Nonacus
Generated by Meeveem AI
"Advancing non-invasive cancer detection through liquid biopsy genomic testing solutions."
About Nonacus
Nonacus develops genomic testing products for cancer detection, treatment selection and monitoring. Based in Birmingham, it combines next generation sequencing with bioinformatic analysis to examine tumour DNA. Its GALEAS range includes bladder cancer testing, hereditary cancer panels and tumour profiling, supporting both tissue and liquid biopsy workflows.
Founded in 2015 by Chris Sale and Lee Silcock, the company aims to reduce reliance on invasive diagnostic procedures. GALEAS Bladder is a UKCA-marked urine test designed to help clinicians decide which patients need further investigation. Nonacus works with scientists and clinicians, while its sister company, Nonacus Clinical Services, delivers clinical testing services.
Connecting science with diagnostics
The published leadership team brings together clinical science, laboratory operations, bioinformatics, data science, software, quality, regulatory and commercial expertise. Nonacus’s development work connects genomic research with tools intended for clinical use, including analysis of genetic changes and monitoring over time.
56
Team Members
2015
Founded
Diagnostics
Sector
On-Site
Work Environment